Article
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Clinical cancer research : an official journal of the American Association for Cancer Research - 14 Apr 2022
Vincenzi Bruno, Napolitano Andrea, Fiocco Marta, Mir Olivier, Rutkowski Piotr, Blay Jean-Yves, Reichardt Peter, Joensuu Heikki, Fumagalli Elena, Gennatas Spyridon, Hindi Nadia, Nannini Margherita, Spalato Ceruso Mariella, Italiano Antoine, Grignani Giovanni, Brunello Antonella, Gasperoni Silvia, De Pas Tommaso, Badalamenti Giuseppe, Pantaleo Maria A, van Houdt Winan J, IJzerman Nikki S, Steeghs Neeltje, Gelderblom Hans, Desar Ingrid M E, Falkenhorst Johanna, Silletta Marianna, Sbaraglia Marta, Tonini Giuseppe, Martin-Broto Javier, Hohenberger Peter, Le Cesne Axel, Jones Robin L, Dei Tos Angelo P, Gronchi Alessandro, Bauer Sebastian, Casali Paolo G
Abstract excerpt
PURPOSE: The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association of dose and other clinicopathologic variables with survival was evaluated in a large multi-institutional European cohort. EXPERIMENTAL DESIGN: Data from 185 patients were retrospectively collected...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.